社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
同源康医药-B(02410)
7.740
-0.390
-4.80%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
莎士比亚的微笑
·
06-04 17:30
$同源康医药-B(02410)$
ASCO点评专家指出，TY-9591的优异数据为EGFR突变NSCLC伴脑转移患者提供了更优的治疗选择，有望改写临床治疗指南
$同源康医药-B(02410)$ ASCO点评专家指出，TY-9591的优异数据为EGFR突变NSCLC伴脑转移患者提供了更优的治疗选择，有望改写临床治疗指南
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
永远的话事人
·
06-03 22:01
$同源康医药-B(02410)$
同源康最近希望跟大盘反着来，那么希望明天大盘多跌一些[开心] [开心]
$同源康医药-B(02410)$ 同源康最近希望跟大盘反着来，那么希望明天大盘多跌一些[开心] [开心]
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
乐山大佛笑哈哈
·
06-02 15:55
$同源康医药-B(02410)$
当前国内创新药政策持续利好，新获批创新药可快速纳入医保谈判，TY-9591若下半年获批，有望在2027年上半年实现快速放量
$同源康医药-B(02410)$ 当前国内创新药政策持续利好，新获批创新药可快速纳入医保谈判，TY-9591若下半年获批，有望在2027年上半年实现快速放量
回复
评论
点赞
1
编组 21备份 2
分享
举报
牛熊两吃
·
06-01
$同源康医药-B(02410)$
同源康目前是习惯了逆势走势，跟大盘有点反着来的意思，明天涨回来？
$同源康医药-B(02410)$ 同源康目前是习惯了逆势走势，跟大盘有点反着来的意思，明天涨回来？
回复
评论
点赞
1
编组 21备份 2
分享
举报
打铁不如李铁
·
05-29
$同源康医药-B(02410)$
近期公司针对核心进展都及时发布了公告，信息披露及时透明，投资者关系管理到位，有效避免了不实信息对股价的影响，维护了市场稳定
$同源康医药-B(02410)$ 近期公司针对核心进展都及时发布了公告，信息披露及时透明，投资者关系管理到位，有效避免了不实信息对股价的影响，维护了市场稳定
回复
评论
点赞
1
编组 21备份 2
分享
举报
龙龙行天下
·
05-28
$同源康医药-B(02410)$
同源康小幅反弹上来，整体表现还是可以，稳步反弹起来
$同源康医药-B(02410)$ 同源康小幅反弹上来，整体表现还是可以，稳步反弹起来
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
乐山大佛笑哈哈
·
05-27
$同源康医药-B(02410)$
短期来看，ASCO数据公布、TY-9591获批都是明确的催化因素，长期来看，TY-9591上市后管线陆续推进，公司成长空间已经打开，具备较好的投资机会
$同源康医药-B(02410)$ 短期来看，ASCO数据公布、TY-9591获批都是明确的催化因素，长期来看，TY-9591上市后管线陆续推进，公司成长空...
回复
评论
点赞
1
编组 21备份 2
分享
举报
if3524 fjd
·
05-26
$同源康医药-B(02410)$
今天终于来了一次比较好的反弹，10厘米大棒确实不错
$同源康医药-B(02410)$ 今天终于来了一次比较好的反弹，10厘米大棒确实不错
回复
评论
点赞
1
编组 21备份 2
分享
举报
打铁不如李铁
·
05-22
$同源康医药-B(02410)$
公司在肺癌、乳腺癌、前列腺癌、ROS1/NTRK融合阳性肿瘤以及KRAS G12C突变肿瘤等多个领域上都有管线布局
$同源康医药-B(02410)$ 公司在肺癌、乳腺癌、前列腺癌、ROS1/NTRK融合阳性肿瘤以及KRAS G12C突变肿瘤等多个领域上都有管线布局
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
G股叶荣添
·
05-21
$同源康医药-B(02410)$
同源康目前还是需要一些资金流入进来，从而推动股价上升
$同源康医药-B(02410)$ 同源康目前还是需要一些资金流入进来，从而推动股价上升
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
同源康医药-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。
05-22
股份购回
2025年年度股东会通函
2025年年度股东会通函
04-29
年度报告
2025年度报告
2025年度报告
03-30
年度报告
截至2025年12月31日止年度年度业绩公告；及建议修订组织章程细则
截至2025年12月31日止年度年度业绩公告；及建议修订组织章程细则
2025-09-19
半年度报告
2025中期报告
2025中期报告
2025-08-31
须予披露的交易
须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途
须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途
2025-08-31
半年度报告
截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则
截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则
2025-08-04
股份发行
完成根据一般授权配售新H股
完成根据一般授权配售新H股
2025-07-29
股份发行
根据一般授权配售新H股
根据一般授权配售新H股
2025-04-29
年度报告
2024年度报告
2024年度报告
2025-03-27
年度报告
截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则
截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则
2024-09-27
半年度报告
2024中期报告
2024中期报告
2024-08-30
半年度报告
截至2024年6月30日止六个月中期业绩公告
截至2024年6月30日止六个月中期业绩公告
2024-08-12
股份发售
全球发售
全球发售
分时
5日
日
周
月
数据加载中...
最高
8.130
今开
8.020
量比
0.57
最低
7.720
昨收
8.130
换手率
0.54%
热议股票
{"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"02410","data":{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":7.74,"timestamp":1780560493007,"preClose":8.13,"halted":0,"volume":2012000,"delay":0,"changeRate":-0.04797047970479711,"floatShares":375457818,"shares":380065818,"eps":-0.8,"marketStatus":"未开盘","change":-0.39,"latestTime":"06-04 16:08:13","open":8.02,"high":8.13,"low":7.72,"amount":15896160,"amplitude":0.050431,"askPrice":7.75,"askSize":12000,"bidPrice":7.74,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.890654,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780623000000},"marketStatusCode":0,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":8.13,"openAndCloseTimeList":[[1780536600000,1780545600000],[1780549200000,1780560000000]],"volumeRatio":0.573857,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.571560942334280","cardData":[{"tweetId":"571560942334280","author":{"authorId":"4218427800237090","idStr":"4218427800237090","name":"莎士比亚的微笑","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> ASCO点评专家指出，TY-9591的优异数据为EGFR突变NSCLC伴脑转移患者提供了更优的治疗选择，有望改写临床治疗指南","plainDigest":"$同源康医药-B(02410)$ ASCO点评专家指出，TY-9591的优异数据为EGFR突变NSCLC伴脑转移患者提供了更优的治疗选择，有望改写临床治疗指南","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1780565427135,"gmtModify":1780565660008,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":49,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/571560942334280","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":123,"displayRows":4,"foldSize":0,"authorId":"4218427800237090"}]},{"cardType":"TWEET","cardId":"TWEET.571273774842056","cardData":[{"tweetId":"571273774842056","author":{"authorId":"4214049281636630","idStr":"4214049281636630","name":"永远的话事人","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康最近希望跟大盘反着来，那么希望明天大盘多跌一些[开心] [开心] ","plainDigest":"$同源康医药-B(02410)$ 同源康最近希望跟大盘反着来，那么希望明天大盘多跌一些[开心] [开心]","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1780495316256,"gmtModify":1780495663292,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":10,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/571273774842056","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":84,"displayRows":4,"foldSize":0,"authorId":"4214049281636630"}]},{"cardType":"TWEET","cardId":"TWEET.570929055586040","cardData":[{"tweetId":"570929055586040","author":{"authorId":"4203843771083212","idStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 当前国内创新药政策持续利好，新获批创新药可快速纳入医保谈判，TY-9591若下半年获批，有望在2027年上半年实现快速放量","plainDigest":"$同源康医药-B(02410)$ 当前国内创新药政策持续利好，新获批创新药可快速纳入医保谈判，TY-9591若下半年获批，有望在2027年上半年实现快速放量","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1780386921356,"gmtModify":1780388336868,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":187,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/570929055586040","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":129,"displayRows":4,"foldSize":0,"authorId":"4203843771083212"}]},{"cardType":"TWEET","cardId":"TWEET.570657391256184","cardData":[{"tweetId":"570657391256184","author":{"authorId":"4136460772891970","idStr":"4136460772891970","name":"牛熊两吃","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":12,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$</a> 同源康目前是习惯了逆势走势，跟大盘有点反着来的意思，明天涨回来？","plainDigest":"$同源康医药-B(02410)$ 同源康目前是习惯了逆势走势，跟大盘有点反着来的意思，明天涨回来？","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1780324859682,"gmtModify":1780326026691,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":177,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/570657391256184","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":82,"displayRows":4,"foldSize":0,"authorId":"4136460772891970"}]},{"cardType":"TWEET","cardId":"TWEET.569437913469072","cardData":[{"tweetId":"569437913469072","author":{"authorId":"4193625296607780","idStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 近期公司针对核心进展都及时发布了公告，信息披露及时透明，投资者关系管理到位，有效避免了不实信息对股价的影响，维护了市场稳定","plainDigest":"$同源康医药-B(02410)$ 近期公司针对核心进展都及时发布了公告，信息披露及时透明，投资者关系管理到位，有效避免了不实信息对股价的影响，维护了市场稳定","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1780027128830,"gmtModify":1780028674540,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":242,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/569437913469072","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":139,"displayRows":4,"foldSize":0,"authorId":"4193625296607780"}]},{"cardType":"TWEET","cardId":"TWEET.569230181122872","cardData":[{"tweetId":"569230181122872","author":{"authorId":"4204683525604390","idStr":"4204683525604390","name":"龙龙行天下","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":9,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康小幅反弹上来，整体表现还是可以，稳步反弹起来","plainDigest":"$同源康医药-B(02410)$ 同源康小幅反弹上来，整体表现还是可以，稳步反弹起来","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1779976436514,"gmtModify":1779976581615,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":312,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/569230181122872","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":69,"displayRows":4,"foldSize":0,"authorId":"4204683525604390"}]},{"cardType":"TWEET","cardId":"TWEET.568812225331544","cardData":[{"tweetId":"568812225331544","author":{"authorId":"4203843771083212","idStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 短期来看，ASCO数据公布、TY-9591获批都是明确的催化因素，长期来看，TY-9591上市后管线陆续推进，公司成长空间已经打开，具备较好的投资机会","plainDigest":"$同源康医药-B(02410)$ 短期来看，ASCO数据公布、TY-9591获批都是明确的催化因素，长期来看，TY-9591上市后管线陆续推进，公司成长空间已经打开，具备较好的投资机会","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1779874375832,"gmtModify":1779874670481,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":349,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/568812225331544","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":147,"displayRows":4,"foldSize":0,"authorId":"4203843771083212"}]},{"cardType":"TWEET","cardId":"TWEET.568509790687376","cardData":[{"tweetId":"568509790687376","author":{"authorId":"4124624486750802","idStr":"4124624486750802","name":"if3524 fjd","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":24,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 今天终于来了一次比较好的反弹，10厘米大棒确实不错","plainDigest":"$同源康医药-B(02410)$ 今天终于来了一次比较好的反弹，10厘米大棒确实不错","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1779804244305,"gmtModify":1779804551643,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":395,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/568509790687376","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":68,"displayRows":4,"foldSize":0,"authorId":"4124624486750802"}]},{"cardType":"TWEET","cardId":"TWEET.566836323890144","cardData":[{"tweetId":"566836323890144","author":{"authorId":"4193625296607780","idStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":7,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 公司在肺癌、乳腺癌、前列腺癌、ROS1/NTRK融合阳性肿瘤以及KRAS G12C突变肿瘤等多个领域上都有管线布局","plainDigest":"$同源康医药-B(02410)$ 公司在肺癌、乳腺癌、前列腺癌、ROS1/NTRK融合阳性肿瘤以及KRAS G12C突变肿瘤等多个领域上都有管线布局","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1779422091006,"gmtModify":1779422092974,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":521,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/566836323890144","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":113,"displayRows":4,"foldSize":0,"authorId":"4193625296607780"}]},{"cardType":"TWEET","cardId":"TWEET.566645434566312","cardData":[{"tweetId":"566645434566312","author":{"authorId":"4218001298160580","idStr":"4218001298160580","name":"G股叶荣添","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 同源康目前还是需要一些资金流入进来，从而推动股价上升","plainDigest":"$同源康医药-B(02410)$ 同源康目前还是需要一些资金流入进来，从而推动股价上升","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1779375554180,"gmtModify":1779375556074,"symbols":["02410"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":286,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/566645434566312","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":72,"displayRows":4,"foldSize":0,"authorId":"4218001298160580"}]}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"21298578","market":"hk","labels":[],"media":"港交所","original_id":"N.HKFKJWr7T5sz","pdf_url":"https://static.tigerbbs.com/603d1586a36a47afbca08a0adcab4ce0","pub_time":1779438600000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025年年度股东会通函","symbol":"02410","title":"2025年年度股东会通函","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0522/2026052200326_c.pdf","us_notice_code":"通函 - [在股东批准的情况下重选或委任董事 / 一般性授权 / 回购股份的说明函件 / 修订宪章文件 / 其他]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2026-05-22 16:30","pubTimestamp":1779438600,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"21172907","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7RqVR3tSL8","pdf_url":"https://static.tigerbbs.com/1027171a8c9a4415aeba426ab6660985","pub_time":1777451640000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025年度报告","symbol":"02410","title":"2025年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0429/2026042900873_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报 / 环境、社会及管治资料/报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2026-04-29 16:34","pubTimestamp":1777451640,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20913979","market":"hk","labels":[],"media":"港交所","original_id":"N.HKAJpyk3tXgk","pdf_url":"https://static.tigerbbs.com/eca2fa5c99d94c6f86a5374ac319aadd","pub_time":1774860180000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年12月31日止年度年度业绩公告；及建议修订组织章程细则","symbol":"02410","title":"截至2025年12月31日止年度年度业绩公告；及建议修订组织章程细则","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0330/2026033000575_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期 / 修订宪章文件]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2026-03-30 16:43","pubTimestamp":1774860180,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20185733","market":"hk","labels":[],"media":"港交所","original_id":"N.HK529G9em8zu","pdf_url":"https://static.tigerbbs.com/baba20cef37d43d9a1b4365303cad8db","pub_time":1758270720000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025中期报告","symbol":"02410","title":"2025中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0919/2025091900443_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-19 16:32","pubTimestamp":1758270720,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20112040","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEBcbBF6ATz","pdf_url":"https://static.tigerbbs.com/375db4bf747e4d53a101c0ea7e90805f","pub_time":1756636620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途","symbol":"02410","title":"须予披露交易 - 认购理财产品；投资及赎回基金权益；及更新全球发售闲置资金用途","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0831/2025083100074_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 其他-杂项]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-08-31 18:37","pubTimestamp":1756636620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20112037","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9qKjV1tTLN","pdf_url":"https://static.tigerbbs.com/23daaef8e7404155822c39fdfb71940a","pub_time":1756636200000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则","symbol":"02410","title":"截至2025年6月30日止六个月中期业绩公告；非执行董事辞任；及建议修订组织章程细则","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0831/2025083100066_c.pdf","us_notice_code":"公告及通告 - [中期业绩 / 修订宪章文件 / 更换董事或重要行政职能或职责的变更]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-31 18:30","pubTimestamp":1756636200,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19944295","market":"hk","labels":[],"media":"港交所","original_id":"N.HKBjBpozdtEZ","pdf_url":"https://static.tigerbbs.com/34fc3516e01d405f8935b05e06943126","pub_time":1754318520000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"完成根据一般授权配售新H股","symbol":"02410","title":"完成根据一般授权配售新H股","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0804/2025080402347_c.pdf","us_notice_code":"公告及通告 - [配售 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-08-04 22:42","pubTimestamp":1754318520,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19918222","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5XNhTGVFfY","pdf_url":"https://static.tigerbbs.com/ca188062973d42f3b71aee148112a82b","pub_time":1753740420000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"根据一般授权配售新H股","symbol":"02410","title":"根据一般授权配售新H股","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0729/2025072900004_c.pdf","us_notice_code":"公告及通告 - [配售 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-07-29 06:07","pubTimestamp":1753740420,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19562509","market":"hk","labels":[],"media":"港交所","original_id":"N.HK6jhALatDTA","pdf_url":"https://static.tigerbbs.com/3655ef960b914b0888916cb27a57c97b","pub_time":1745916120000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024年度报告","symbol":"02410","title":"2024年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0429/2025042901084_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报 / 环境、社会及管治资料/报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-29 16:42","pubTimestamp":1745916120,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19298545","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5kKrBbdctD","pdf_url":"https://static.tigerbbs.com/718c98826c324bf0b2e29802f28dd06c","pub_time":1743083400000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则","symbol":"02410","title":"截至2024年12月31日止年度年度业绩公告；非执行董事辞任；及建议修订组织章程细则","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0327/2025032702334_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期 / 更换董事或重要行政职能或职责的变更 / 修...更多]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-27 21:50","pubTimestamp":1743083400,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18653724","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDa8ffoZeXZ","pdf_url":"https://static.tigerbbs.com/3bf20bbd552f4fde9768a429aa07ab21","pub_time":1727426700000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024中期报告","symbol":"02410","title":"2024中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0927/2024092700920_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-27 16:45","pubTimestamp":1727426700,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18559041","market":"hk","labels":[],"media":"港交所","original_id":"N.HKJ6zpjRgpMT","pdf_url":"https://static.tigerbbs.com/be1fa360987748aa9d1e9642550fe2d3","pub_time":1725007620000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年6月30日止六个月中期业绩公告","symbol":"02410","title":"截至2024年6月30日止六个月中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083000942_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-30 16:47","pubTimestamp":1725007620,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18458575","market":"hk","labels":[],"media":"港交所","original_id":"N.HK8CzhcJraXG","pdf_url":"https://static.tigerbbs.com/52b2dfd43b1b4917960f378086db6cae","pub_time":1723414560000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"02410","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0812/2024081200006_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2024-08-12 06:16","pubTimestamp":1723414560,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"stockEarnings":[{"period":"1week","weight":-0.1052},{"period":"1month","weight":-0.187},{"period":"3month","weight":-0.3027},{"period":"6month","weight":-0.4471},{"period":"1year","weight":-0.6657},{"period":"ytd","weight":-0.4096}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":-0.0249},{"period":"3month","weight":-0.0196},{"period":"6month","weight":-0.0319},{"period":"1year","weight":0.0676},{"period":"ytd","weight":-0.0147}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"aProfile":null}}}